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Abstract
Aims/Hypothesis
Diabetic peripheral neuropathy is a frequent and severe complication of diabetes. As Matrix-
gla-protein (MGP) is expressed in several components of the nervous system and is
involved in some neurological disease, MGP could play a role in peripheral nervous system
homeostasis. The aim of this study was to evaluate factors associated with sensitive dia-
betic neuropathy in Type 2 Diabetes, and, in particular, dephospho-uncarboxylated MGP
(dp-ucMGP), the inactive form of MGP.
Methods
198 patients with Type 2 Diabetes were included. Presence of sensitive diabetic neuropathy
was defined by a neuropathy disability score (NDS)�6. Plasma levels of dp-ucMGP were
measured by ELISA.
Results
In this cohort, the mean age was 64+/-8.4 years old, and 80% of patients were men. Periph-
eral neuropathy was present in 15.7% of the patients and was significantly associated (r =
0.51, p<0.0001) with dp-ucMGP levels (β = -0.26, p = 0.045) after integrating effects of
height (β = -0.38, p = 0.01), insulin treatment (β = 0.42, p = 0.002), retinopathy treated by
laser (β = 0.26, p = 0.02), and total cholesterol levels (β = 0.3, p = 0.03) by multivariable
analysis.
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Conclusions
The association between diabetic neuropathy and the inactive form of MGP suggests the
existence of new pathophysiological pathways to explore. Further studies are needed to
determine if dp-ucMGP may be used as a biomarker of sensitive neuropathy. Since dp-
ucMGP is a marker of poor vitamin K status, clinical studies are warranted to explore the
potential protective effect of high vitamin K intake on diabetic peripheral neuropathy.
Introduction
Diabetic peripheral neuropathy is a frequent complication of diabetes. It affects about 10 to
15% of patients with Type 2 Diabetes at diagnosis and up to 50% after 10 years of disease dura-
tion [1]. Diabetic neuropathy is associated with high morbidity and mortality [2], because of
increased risk for foot ulceration and amputation [3], and for poor quality of life and depres-
sion [4]. So, it is related to high healthcare costs [5]. The main clinical characteristic of diabetic
peripheral neuropathy is a decrease of distal sensitivity that represents the most important risk
factor of foot ulceration in patients with diabetes. In 2019, ADA guidelines recommended an
annual clinical screening to diagnose sensitive diabetic neuropathy [1]. ADA recommenda-
tions for screening and diagnosis include a careful history and assessment of either tempera-
ture or pinprick sensation (small-fiber function) and vibration sensation using a 128-Hz
tuning fork (for large-fiber function). All patients should have annual 10-g monofilament test-
ing to identify feet at risk for ulceration and amputation. Electrophysiological testing or refer-
ral to a neurologist is not recommended for screening, except in situations where the clinical
features are atypical, the diagnosis is unclear, or a different etiology is suspected [1].
Mechanisms involved in diabetic neuropathy are not clearly understood. The main hypoth-
esis is that chronic glucotoxicity and lipotoxicity lead to oxidative stress, inflammation, and
mitochondrial dysfunction and finally to nerve damage with neuron degeneration and demye-
lination [6, 7].
Matrix gla protein (MGP) is an 84 amino acids protein containing five glutamic acid resi-
dues (glu residues) and three serine residues. MGP exists in inactive and active forms [8]. The
activation of MGP is obtained after a vitamin K dependent gamma-glutamyl carboxylation of
glutamic acid residues (forming gla residues) and a phosphorylation of serine residues [9, 10].
Desphospho-uncarboxylated MGP (dp-ucMGP) represents therefore the inactive form of
MGP. MGP was initially isolated from bone tissue but it is also expressed by chondrocytes,
vascular smooth muscle cells, endothelial cells but also neurons and glial cells [11, 12]. More-
over, several studies suggest that MGP plays a role in the nervous system. First, in 2005, a
novel mutation of MGP associated with high level of inactive dp-ucMGP is described and asso-
ciated with neurological manifestations, abnormalities of brain’s white matter and optic nerve
atrophy, in addition to typical manifestations of Keutel syndrome [13, 14], suggesting a link
between MGP activity and nervous system pathophysiology. Then, Goritz et al have demon-
strated that MGP is expressed by neurons, and is regulated by glial cells [12]. Finally, some
studies reveal also that MGP could be implicated in neurological disease, as glioblastoma [15],
and Alzheimer disease [16].
Given that the pathogenesis of diabetic neuropathy remains unclear and that MGP could be
involved in nervous system pathophysiology, we hypothesize that MGP may be involved in
diabetic peripheral neuropathy development. The objective of this study is to evaluate the clini-
cal and biological markers, in particular inactive dp-ucMGP, associated with diabetic periph-
eral neuropathy on patients with Type 2 Diabetes.
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Material and methods
Study design
This study is a cross-sectional ancillary study to the prospective DIACART cohort17. DIA-
CART cohort was initially designed to study the clinical and biological variables associated
with peripheral arterial calcification and other diabetic complications such as diabetic neurop-
athy. In this cohort, diabetic peripheral neuropathy was accurately assessed with a careful foot
examination to calculate the NDS score [7]. 198 Patients were recruited in the diabetes and
cardiology departments, in the Pitie´-Salpêtrière hospital (APHP, Paris, France), over eight
months, from November 2011 to July 2012. They were subsequently prospectively assessed in
a cardio-metabolic clinical research center (INSERM, CIC 1421) for clinical phenotyping and
bio banking of their blood samples.
Participants
DIACART cohort was initially designed to study the clinical and biological variables associated
with diabetic complications [17]. The study focused on patients with Type 2 Diabetes, at high
cardiovascular risk. Inclusion criteria were Type 2 Diabetes with at least one of the following
criteria: coronary artery disease or peripheral arterial occlusive disease or age>50 years for
men or>60 years for women. Exclusion criteria were an estimated glomerular filtration rate
calculated with the modification of diet in renal disease <30ml/min and a history of lower
limb angioplasty and/or bypass. The peripheral nerve deficit of nondiabetic origin (e.g. alco-
hol, neurotoxic medications (e.g., chemotherapy), vitamin B12 deficiency, hypothyroidism,
renal disease, malignancies (e.g., multiple myeloma), infections (e.g., HIV, HCV), chronic
inflammatory demyelinating neuropathy, inherited neuropathies, compression due to verte-
bral disk herniation, and vasculitis) was excluded through a careful medical history review, a
differential test or both.
Informed consent and ethical aspect
The study was approved by the local ethics committee (PARIS VI CPP) and registered in Clini-
calTrials.gov (Identifier: NCT02431234). All patients were informed on the study objectives
and procedure. Participants gave their written informed consent to participation. All methods
were carried out in accordance with relevant guidelines and regulations.
Procedure
Data collection, including a clinical evaluation and blood tests, were realized during a one-day
hospitalization in a cardio-metabolic clinical research center.
Diabetic peripheral neuropathy
In this cohort, diabetic peripheral neuropathy was accurately assessed with a careful foot exam-
ination, including several physical tests [7]. Diabetic peripheral neuropathy was assessed by
the modified neuropathy disability score (NDS), scoring from 0 to 10 [18]. NDS assesses vibra-
tion sensory on the great toe using 128-Hz tuning fork, temperature sensory on dorsum of the
foot using tubes of ice or warm water, pinprick sensory applying pin near to big toe nail and
Achilles reflex. Each sensory test scores 0 for normal and 1 for abnormal sensation, for each
foot. Achilles reflex score 0 if they are present, 1 if they are present with reinforcement and 2 if
they are absent, for each foot. NDS� 6 allows the diagnosis of diabetic peripheral neuropathy
[19]. The NDS was also used as a continuous variable to assess magnitude of peripheral neu-
ropathy because NDS score is a validated and widely used score for detecting neuropathy.
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Clinical data
During the patient interview, the physician collected medical information about personal dis-
ease history, comorbidities and treatment. Clinical tests were conducted by a physician blinded
to blood tests results.
Biochemical measures
Blood and urine samples were collected in the morning fasting for the measurement of bio-
chemistry analyses including hemoglobin A1c (HbA1c), high-sensitivity C-reactive protein
(hsCRP), estimated glomerular filtration rate (eGFR) by modification of diet in renal disease
(MDRD), urinary albumin/creatinine ratio, serum calcium corrected for albumin, serum
phosphorus, total cholesterol, triglycerides and IL-6.
Assays were developed to measure dp-ucMGP in plasma [14]. These assays were conducted
after the samples freezing, storage at -80˚C and thawing. Dp-ucMGP levels were measured by
a dual-antibody ELISA. The capture antibody was directing against the non-phosphorylated
MGP sequence 3–15 (mAb-dpMGP; VitaK BV, Maastricht, The Netherlands) and the detect-
ing antibody was directed against the uncarboxylated MGP sequence 35–49 (mAb-ucMGP;
VitaK BV). Intra-assay variability was 5.6% for dp-ucMGP. Inter-assay variability was 9.9% for
dp-ucMGP. Dp-ucMGP was measured in archived samples of 81 age-matched controls. The
mean levels were respectively 557+/-277 pmol/l (median: 522 pmol/l).
Statistical analyses
Data were described as mean +/- standard deviation of the mean or frequency, as appropriate.
Comparison of quantitative variables was performed using Student’s t test or Mann-Whitney
test, when variables were normally and non-normally distributed, respectively. Comparison of
qualitative variables was performed using χ2 test. Pearson’s coefficient (r) was used to assess
association between quantitative variables. A 95% confidence interval for the correlation coef-
ficient was calculated using Fisher’s method (Prism 6; GraphPad Software, Inc). Multivariable
analyses were performed by ANCOVA (continuous NDS scoring) or logistic regression (Pres-
ence/absence of neuropathy defined by NDS�6/<6). Only covariates with significant univari-
ate association (In bold, in Tables 1 and 2) with NDS were further integrated for multivariate
analyses (XLstat-software, Addinsoft1, New-York). For multivariate analysis, beta-coeffi-
cients (β) were calculated to allow for direct comparison of the relative influence of the explan-
atory variables on the dependent variable, and their significance (P�0.05 considered
significant).
In this cohort (n: 198), the study had a power�80% to detect a significant correlation (with
r�0.2, α-risk: 0.05, Student approximation) between each clinical or biological variable and
NDS score.
Results
Baseline characteristics
Clinical and biological characteristics at baseline for the total cohort, and for patients with and
without neuropathy are described in Table 1. Finally, 198 patients were included in the DIA-
CART study, 80% of whom were men. Study participants were young-old (64+/-8.4 years old)
and overweight (mean BMI of 29,16±5.3 kg/m2) patients. Their mean height was 1.7+/-0.08
meters. Diabetes duration was 14.6+/-9.3 years, and mean HbA1c was 7.8%+/-1.5% (61.8
+/-16.2 mmol/L). Concerning diabetes comorbidities, 14.1% of patients had a retinopathy
treated with laser, 36% had a urinary albumin/creatinine ratio >3 mg/mmol, and mean eGFR
Matrix gla protein and diabetic peripheral neuropathy
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calculated by MDRD was 76+/-20 ml/min. Mean NDS was 2.4+/-2.4 points, and 15.7% of sub-
jects had a diabetic peripheral neuropathy, defined by NDS�6. The mean level of dp-uc MGP
was 627 +/-451 pmol/l.
Factors associated with diabetic neuropathy (defined by NDS�6)
Patients with neuropathy were significantly taller (173 cm vs 169 cm, p = 0.009) than patients
without neuropathy. Cholesterol total was significantly lower in patients with neuropathy
compared to patients without neuropathy (3.8 mmol/L vs 3.4 mmol/L, p = 0.02). Retinopathy
treated with laser (32 vs 11%, p = 0.003), urinary albumin/creatinine ratio >3 mg/mmol (61 vs
31%, p = 0.001), coronary arterial disease (90 vs 73%, p = 0.04) and insulin treatment (77 vs
42%, p = 0.0003) were significantly more common in patients with neuropathy. Age, sex ratio,
diabetes duration and HbA1c were not different between patients with and without neuropa-
thy (Table 1). Dp-ucMGP levels were significantly higher in patients with neuropathy than in
those without neuropathy (821 vs 591 pmol/l respectively, p = 0.009). In multivariate analysis
integrating all significant covariates (retinopathy treated with laser, urinary albumin/creati-
nine ratio, coronary arterial disease, insulin treatment and quantitative variables in bold, in
Tables 1 and 2), presence of neuropathy defined by NDS score�6 was still associated
Table 1. Baseline characteristics of the patients.
Characteristics Total cohort Neuropathy (NDS�6) Without neuropathy (NDS<6) p-value
N (%) 198 31 (15.7) 167 (84.3) -
Age, years 64±8.4 64±8.6 64±8.4 ns
Male, n(%) 158 (79.8) 26 (83.9) 132(79) ns
Height (cm) 170±8 173±7 169±8 0.009
BMI (Kg/m2) 29,16±5.3 30,23±5.5 28,97±5.2 ns
Diabetes duration, years 14.6±9.3 14.6±10.2 14.6±9.2 ns
Hypertension, n (%) 163 (82.3) 28 (90.3) 135 (80.8) ns
NDS score, points 2.4±2.4 6.8±1.5 1.6±1.5 <0.0001
Retinopathy treated with laser, n(%) 28 (14.1) 10(32.3) 19(11.3) 0.003
Coronary arterial disease, n(%) 150 (75.8) 28 (90.3) 122 (73.05) 0.04
Ischemic stroke, n(%) 14 (7.1) 2(6.5) 12(7.2) ns
eGFR calculated by MDRD, mL/min 76±20 72±20 77±20 ns
Urinary albumin /creatinine ratio>3 (mg/mmol), n(%) 71 (35.9) 19(61.3) 52 (31.1) 0.001
Insulin treatment, n(%) 94 (47.5) 24(77.4) 70(41.9) 0.0003
HbA1c, mmol/mol 61.8±16.2 66.6±20.5 60.9±15.2 ns
HbA1c, % 7.8±1.5 8,2±1.9 7.7±1.4 ns
hsCRP, mg/L 2.2±2.5 2.4±2.8 2.2±2.5 ns
IL-6, pg/mL 5±22 4.6±3.4 5.3±24 ns
Corrected calcium, mmol/L 2.3±0.1 2.3±0.3 2.3±0.1 ns
Phosphorus, mmol/L 1.02±0.15 1.02±0.14 1.02±0.16 ns
Triglycerides, mmol/L 1.6±1.1 1.5±0.8 1.6±1.1 ns
Total cholesterol, mmol/L 3.7±0.9 3.4±0.8 3.8±0.9 0.02
dp-ucMGP, pmol/L 627±451 821±703 591±379 0.009
Quantitative variables are represented by mean ± standard deviation. Data are given as the number (percentage) for binary variables. Data are no significant (ns) if
p>0.05. Significant differences between patients with and without neuropathy are in bold.
Abbreviations: BMI body mass index, eGFR MDRD estimated glomerular filtration rate calculated with the modification of diet in renal disease formula, HbA1c
haemoglobin A1C, hsCRP high sensitivity C-reactive protein, IL-6 interleukin 6, dp-ucMGP dephospho-uncarboxylated matrix gla protein, NDS neuropathy disability
score.
https://doi.org/10.1371/journal.pone.0229145.t001
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(r = 0.51, p<0.0001) with dp-ucMGP levels (β = -0.26, p = 0.045), height (β = -0.38, p = 0.01),
insulin treatment (β = 0.42, p = 0.002), retinopathy treated by laser (β = 0.26, p = 0.02), and
total cholesterol level (β = 0.3, p = 0.03) (Table 3).
Factors associated with continuous NDS scoring
In univariate analysis (Table 2), NDS was positively associated with height (r = 0.25, p =
0.0004), HbA1c (r = 0.21, p = 0.04) and dp-ucMGP (r = 0.22, p = 0.002). NDS was negatively
associated with eGFR (r = -0.16, p = 0.03). In multivariate analysis integrating all significant
covariates (in bold, in Tables 1 and 2), NDS scoring was still associated (r = 0.51, p<0.0001)
with dp-ucMGP levels (β = 0.16, p = 0.025), height (β = 0.29, p<0.0001), HbA1c (β = 0.19,
p = 0.006), insulin treatment (β = 0.19, p = 0.007), retinopathy treated by laser (β = 0.16,
p = 0.015) and urinary albumin/creatinine ratio>3 mg/mmol (β = 0.14, p = 0.031) (Table 4).
Table 2. Univariate analysis: Correlations between clinical and biological variables and NDS.
r, [CI 95%] p-value
Age 0.07 [-0.08; 0.20] ns
Height 0.25 [0.11; 0.38] 0.0004
Body mass index (kg/m2) 0.09 [-0.05; 0.23] ns
Diabetes duration 0.03 [-0.11; 0.17] ns
eGFR -0.16 [-0.29; -0.02] 0.03
HbA1c 0.21 [0.08; 0.34] 0.04
HsCRP, mg/L 0.03 [-0.11; 0.17] ns
IL-6, pg/mL 0.08 [-0.07; 0.21] ns
Corrected calcium, mmol/L 0.08 [-0.06; 0.22] ns
Phosphorus, mmol/L 0 [-0.14; 0.14] ns
Triglycerides -0.07 [-0.21; 0.07] ns
Total cholesterol -0.11 [-0.25; 0.02] ns
dp-ucMGP 0.22 [0.08; 0.34] 0.002
Correlations were performed by Pearson’s coefficient (r). 95% confidence interval of the correlation coefficient was
assessed using Fisher’s method, and is presented in brackets. Correlations are significant if p<0.05. Significant results
are presented in bold.
Abbreviations: BMI body mass index, eGFR MDRD estimated glomerular filtration rate calculated with the
modification of diet in renal disease formula, HbA1c haemoglobin A1C, hsCRP high sensitivity C-reactive protein,
IL-6 interleukin 6, dp-ucMGP dephospho-uncarboxylated matrix gla protein, NDS neuropathy disability score.
https://doi.org/10.1371/journal.pone.0229145.t002
Table 3. Multivariate analysis: Correlations between clinical and biological variables and diabetic neuropathy
(NDS� 6).
β, [95% confidence interval] p-value
Height -0.38, [-0.67–0.09] 0.01
Retinopathy treated with laser 0.26, [0.05–0.47] 0.02
Insulin treatment 0.42, [0.15–0.7] 0.002
Total cholesterol 0.3, [0.03–0.57] 0.03
dp-ucMGP -0.26, [-0.51–0.01] 0.045
Multivariate analysis was performed using ANCOVA. 95% confidence interval of the standardized coefficient is
presented in brackets. Correlations are significant if p<0.05. Significant results are presented in bold.
Abbreviations: β: standardized coefficient, dp-ucMGP dephospho-uncarboxylated matrix gla protein, NDS
neuropathy disability score.
https://doi.org/10.1371/journal.pone.0229145.t003
Matrix gla protein and diabetic peripheral neuropathy
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Discussion
This study reveals that peripheral neuropathy, defined by a NDS score�6, in type 2 diabetic
patients is significantly associated with height, insulin treatment, retinopathy treated with laser,
total cholesterol and, particularly to dp-ucMGP plasma levels. These factors, HbA1c and urinary
albumin/creatinine ratio>3 mg/mmol are also associated with the magnitude of NDS scoring.
Height, poor glycemic control and dyslipidemia are known risk factors of diabetic neuropa-
thy [4]. We don’t find any significant association between BMI and neuropathy in our study,
probably because BMI formula includes height, which is maybe a more important marker of
diabetic peripheral neuropathy due to the length-dependent presentation of this neuropathy
[20]. Furthermore, BMI is not also associated with neuropathy in the DIACART study proba-
bly because majority of the patients included were overweight or obese (mean BMI 29.16
+/-5.3 Kg/m2). Although insulin is considered as a neurotrophic factor and although low-dose
insulin can have beneficial effects on diabetic neuropathy, insulin use is associated with dia-
betic neuropathy in the DIACART study [21]. Retinopathy and nephropathy are usual comor-
bidities of diabetic neuropathy, explaining their association in this study [4]. In the same way,
age and gender are not related to neuropathy in our population because most of the patients
included in this study were male (80%) and elderly (mean age 64+/-8.4 years old).
The most important and original result is the association between dp-ucMGP plasma levels
and diabetic neuropathy. Moreover, dp-ucMGP plasma levels increased with the continuous
NDS scoring.
This association could be explained by several hypotheses.
We can suppose that the association between dp-ucMGP and neuropathy could directly
result from MGP involvement in pathophysiology of diabetic peripheral neuropathy. Indeed,
MGP is a protein from extracellular matrix mainly expressed in osteoarticular and vascular
systems, but Goritz et al have shown that MGP is also expressed by neurons and glial cells [12].
The main ligand of MGP is Bone Morphogenetic Protein-2 (BMP-2) [22] and some data show
that MGP, via modulation of BMP-2 signaling, could participate in the early differentiation
and growth of neurons, in dendrites formation, in the development of mature Schwann cells
and in the myelination [23–26]. Furthermore, MGP can also interact with fibronectin, which
is involved in axon regeneration by its interaction with Schwann cells [27–29]. Consequently,
an excess of inactive form of MGP (i.e., dp-ucMGP), could be associated with nerve damage
and a source of axon regeneration loss, two pathological conditions observed in diabetic
neuropathy.
Table 4. Multivariate analysis: Correlations between clinical and biological variables and continuous NDS
scoring.
β, [95% confidence interval] p-value
Height 0.29, [0.16–0.41] <0.0001
Retinopathy treated with laser 0.16, [0.03–0.29] 0.015
Insulin treatment 0.19, [0.05–0.33] 0.007
Urinary albumin/creatinine ratio>3 0.14, [0.01–0.28] 0.031
HbA1c 0.19, [0.06–0.33] 0.006
dp-ucMGP 0.16, [0.02–0.29] 0.025
Multivariate analysis was performed using ANCOVA. 95% confidence interval of the standardized coefficient is
presented in brackets. Correlations are significant if p<0.05. Significant results are presented in bold.
Abbreviations: β: standardized coefficient, dp-ucMGP dephospho-uncarboxylated matrix gla protein, HbA1c
haemoglobin A1C, NDS neuropathy disability score.
https://doi.org/10.1371/journal.pone.0229145.t004
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However, dp-ucMGP is primarily an inverse marker for vitamin K status, and the associa-
tion between dp-ucMGP and neuropathy suggests that poor vitamin K status is an indepen-
dent risk factor for diabetic peripheral neuropathy. Comparison of different MGP assays
showed that the dp-ucMGP assay is particularly suited to assess vascular vitamin K status and
dp-ucMGP is then considered as the most sensitive biomarker for poor vitamin K status pres-
ently known [30]. Poor vitamin K status, estimated by dp-ucMGP, has been before described
as associated with increased cardiovascular risk in Type 2 Diabetes [31]. Here we show, for the
first time, an association between vitamin K status and diabetic peripheral neuropathy. The
role of vitamin K in the nervous system was initially described via observations of microceph-
aly, optic atrophy and mental retardation resulting from fetal exposure to warfarin [32]. A
recent study has shown that vitamin K enhances, during remyelination, the production of
brain sulfatides, the sulfated form of galactosylceramides [33]. Decreases in myelin sulfatides
content have been implicated as important factors in the disruption of myelin stability and
function [34]. Furthermore, vitamin K seems to have survival-promoting effect on neurons
[35]. We can therefore hypothesize that low vitamin K status could be associated with myelin
alteration and cytotoxic effects on neurons in peripheral nerve tissue. Further studies are
needed to confirm the role of vitamin K in peripheral diabetic neuropathy.
Vitamin K is an essential cofactor for the maturation of several proteins, not only for MGP.
We cannot therefore exclude that the association of poor vitamin K status with diabetic
peripheral neuropathy may also be a marker of the involvement of another vitamin K-depen-
dent protein that is important for the neural system.
Circulating inactive dp-ucMGP could also be useful as a biomarker of diabetic neuropathy.
The diagnosis of diabetic neuropathy is mainly clinical, based on sensory tests. But, these tests
need to be associated to increase their sensitivity, are operator-dependent and time-consum-
ing. Different surveys revealed that about only 65% of patients with diabetes yearly had a foot
examination by a physician [36]. So, biomarker of diabetic neuropathy could be useful for clin-
ical practice. Several biomarkers have been suggested, as neuron-specific enolase, toll-like
receptor 4 or tumor necrosis factor alpha (TNF-α), but they are not specific of diabetic neurop-
athy [37, 38]. Further studies are needed to clarify if dp-ucMGP could be a good biomarker in
this field.
There is some data showing that dp-ucMGP is associated with several micro and macro-
vascular complications of diabetes, including diabetic nephropathy, retinopathy, vascular stiff-
ness and vascular calcification [39–41]. Although dp-ucMGP has been repeatedly associated
with vascular calcification and cardiovascular disease, dp-ucMGP is not associated in our
study with coronary arterial disease (S1 Table) [39, 41]. As observed by others, dp-ucMGP is
associated negatively with eGFR estimated by MDRD and with albuminuria (S1 Table) [39,
40]. However we don’t find any association between dp-ucMGP and retinopathy treated by
laser (S1 Table) despite some data suggesting that dp-ucMGP could be a marker of retinal
health [42]. Additional studies are needed to explore specifically these associations in patients
with diabetes.
Since dp-ucMGP is a vitamin K dependent protein, diabetic peripheral neuropathy in our
study is associated with poor vitamin K status. Clinically, this gives possibilities to explore
options for treatment with vitamin K supplements and especially to put in place preventive
measures in diabetic patients at risk of peripheral neuropathy. The treatment of diabetic neu-
ropathy remains currently mainly symptomatic, based on pain treatment. Targeted therapies
have been developed: aldose reductase inhibitors, blocking the polyol pathway, protein kinase
C inhibitors, and aminoguanidine, preventing the synthesis of age glycation end products.
Despite promising results in pre-clinical animal models, clinical trials haven’t demonstrated
any benefit in man [43–46]. Vitamin K supplementation is safe in human and interventional
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studies are needed to determine if vitamin K supplementation could prevent diabetic periph-
eral neuropathy [47, 48].
So, further studies are really warranted to better understand the role of MGP or other vita-
min K dependent protein in the peripheral nervous system. These studies could be led in larger
cohorts of patients with Type 2 Diabetes patients, and in cohorts of patients with Type 1 Dia-
betes or with other neuropathies, in order to analyze if this association is specific to diabetic
peripheral neuropathy or not. Depending on the results of these studies, MGP could be used
in diabetic neuropathy for diagnosis, prediction or therapeutic purposes via vitamin K
supplementation.
The strengths of this study are the accurate diagnosis of diabetic neuropathy by a validated
score (NDS), and by the same physician for all patients. Although electrophysiological tests
and pathological tests, that are gold standards for the evaluation of diabetic polyneuropathy,
were not performed in the DIACART study, we used NDS score, a largely validated test for
neuropathy diagnosis [18, 49–56]. NDS is well correlated with neurophysiological and sural
nerve morphometric abnormalities in patients with diabetes [49, 51, 57–59]. So the NDS is a
widely used and widely accepted scoring test for diabetic neuropathy. Moreover, in the DIA-
CART study, most of the common risk factors for neuropathy were associated to NDS score.
The subject of this study is innovative. Indeed, this is the first study to concomitant evaluate
dp-ucMGP (i.e. low vitamin K status) and peripheral neuropathy in patients with Type 2 Dia-
betes and we describe here, for the first time, their association. The study would have been
strengthened by the presence of a control group of non-diabetic participants, so that they
could have been compared with diabetic patients. Other limitations of this study are the small
number of patients with a neuropathy, the cross-sectional design which allows only association
but not causal relationships and the absence of the gold standard test, sural nerve biopsy, to
define diabetic neuropathy.
To conclude, this study suggests that that dp-ucMGP and poor vitamin K status are associ-
ated with peripheral diabetic neuropathy in Type 2 Diabetes and that dp-ucMGP could be a
biomarker of choice to identify subjects at risk of diabetic neuropathy. Further studies are war-
ranted to precise if circulating MGP is a biomarker and/or a causal factor of diabetic neuropa-
thy. Then fundamental experiments and prospective clinical studies are needed to clarify the
role of MGP in diabetic neuropathy, and if this protein could be used as biomarker or as thera-
peutic target in diabetic neuropathy via vitamin K supplementation.
Supporting information
S1 Table. Correlations between dp-ucMGP and coronary arterial disease and other micro-
vascular complications of diabetes.
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